McKesson Co. (NYSE:MCK) has been given a consensus rating of “Hold” by the fourteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $147.56.
A number of research analysts recently commented on the company. Bank of America set a $160.00 target price on McKesson and gave the company a “buy” rating in a research note on Wednesday, July 31st. ValuEngine lowered McKesson from a “sell” rating to a “strong sell” rating in a research note on Friday, August 30th. Morgan Stanley upped their target price on McKesson from $130.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 27th. Wolfe Research lowered McKesson from an “outperform” rating to a “peer perform” rating in a research note on Monday, August 5th. Finally, Deutsche Bank assumed coverage on McKesson in a research note on Thursday, September 12th. They issued a “hold” rating and a $155.00 target price for the company.
Shares of NYSE MCK traded up $1.41 during trading hours on Friday, reaching $147.11. The stock had a trading volume of 67,099 shares, compared to its average volume of 1,518,303. The business’s fifty day moving average is $143.15 and its two-hundred day moving average is $130.57. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.01 and a quick ratio of 0.58. The company has a market cap of $26.58 billion, a price-to-earnings ratio of 10.85, a PEG ratio of 1.45 and a beta of 1.13. McKesson has a twelve month low of $106.11 and a twelve month high of $150.82.
McKesson (NYSE:MCK) last issued its earnings results on Wednesday, July 31st. The company reported $3.31 EPS for the quarter, beating analysts’ consensus estimates of $3.04 by $0.27. The business had revenue of $55.73 billion during the quarter, compared to analyst estimates of $54.03 billion. McKesson had a return on equity of 30.73% and a net margin of 0.27%. McKesson’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.90 earnings per share. Sell-side analysts forecast that McKesson will post 14.39 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Tuesday, September 3rd will be given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 1.11%. This is a boost from McKesson’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, August 30th. McKesson’s dividend payout ratio is 12.09%.
In other McKesson news, SVP Sundeep G. Reddy sold 422 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $143.79, for a total value of $60,679.38. Following the sale, the senior vice president now directly owns 1,268 shares in the company, valued at $182,325.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Lori A. Schechter sold 2,500 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $144.40, for a total value of $361,000.00. Following the completion of the sale, the executive vice president now owns 4,535 shares in the company, valued at $654,854. The disclosure for this sale can be found here. Insiders sold 4,218 shares of company stock worth $611,738 over the last quarter. Company insiders own 0.88% of the company’s stock.
Large investors have recently made changes to their positions in the business. Flinton Capital Management LLC grew its position in McKesson by 37.6% in the second quarter. Flinton Capital Management LLC now owns 14,926 shares of the company’s stock valued at $2,006,000 after acquiring an additional 4,080 shares during the period. Cerebellum GP LLC bought a new stake in shares of McKesson during the first quarter worth $318,000. Commonwealth Equity Services LLC grew its holdings in shares of McKesson by 1.0% during the second quarter. Commonwealth Equity Services LLC now owns 46,991 shares of the company’s stock worth $6,315,000 after purchasing an additional 472 shares during the last quarter. Busey Wealth Management grew its holdings in shares of McKesson by 7.1% during the second quarter. Busey Wealth Management now owns 26,511 shares of the company’s stock worth $3,562,000 after purchasing an additional 1,768 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of McKesson by 39.0% during the second quarter. Parallel Advisors LLC now owns 912 shares of the company’s stock worth $122,000 after purchasing an additional 256 shares during the last quarter. Hedge funds and other institutional investors own 86.32% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: What is the significance of a dead cat bounce?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.